The rs41291957 polymorphism of miR-143/145 and cancer risk: a case-control study and meta-analysis

Nucleosides Nucleotides Nucleic Acids. 2023;42(6):478-494. doi: 10.1080/15257770.2022.2157436. Epub 2022 Dec 19.

Abstract

Recently, the rs41291957 polymorphism in the promoter region of miR-143/145 has been repeatedly investigated for its contribution to cancer susceptibility. However, the results remain conflicting rather than conclusive, which calls for further investigations. Therefore, we here conducted a case-control study and meta-analysis to explore the association between rs41291957 and cancer risk. In the case-control study, a total of 2277 cancer patients (lung, liver, gastric and colorectal cancers) and 800 normal controls were recruited, the genotyping of rs41291957 was performed with polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and Sanger sequencing. In the meta-analysis, 5 previously published studies and our present study were included, the STATA 14.0 software was applied to conduct all statistical analyses. The results of case-control study showed that rs41291957 was significantly associated with the risk of gastric cancer, colon cancer, rectal cancer, and colorectal cancer in Hubei Han Chinese population. The results of meta-analysis demonstrated that rs41291957 was significantly associated with overall cancer risk, especially colorectal cancer risk and lung cancer risk. Collectively, the rs41291957 polymorphism of miR-143/145 may be a plausible susceptible locus for cancer risk, which should be validated in future studies with larger samples in different ethnic populations.

Keywords: cancer risk; meta-analysis; miR-143/145 cluster; rs41291957.

Publication types

  • Meta-Analysis

MeSH terms

  • Case-Control Studies
  • Colonic Neoplasms*
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • MicroRNAs* / genetics
  • Polymorphism, Single Nucleotide

Substances

  • MicroRNAs
  • MIRN143 microRNA, human